Vanguard Group Inc. Has $330.42 Million Stock Position in Corcept Therapeutics Incorporated $CORT

Vanguard Group Inc. lowered its holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT) by 0.4% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 9,494,822 shares of the biotechnology company’s stock after selling 42,249 shares during the period. Vanguard Group Inc. owned 0.09% of Corcept Therapeutics worth $330,420,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Advisory Services Network LLC acquired a new stake in Corcept Therapeutics in the 3rd quarter valued at approximately $25,000. Clearstead Advisors LLC grew its holdings in Corcept Therapeutics by 163.6% in the 3rd quarter. Clearstead Advisors LLC now owns 311 shares of the biotechnology company’s stock valued at $26,000 after buying an additional 193 shares during the last quarter. Hantz Financial Services Inc. grew its holdings in Corcept Therapeutics by 598.5% in the 3rd quarter. Hantz Financial Services Inc. now owns 461 shares of the biotechnology company’s stock valued at $38,000 after buying an additional 395 shares during the last quarter. Larson Financial Group LLC grew its holdings in Corcept Therapeutics by 2,326.3% in the 3rd quarter. Larson Financial Group LLC now owns 461 shares of the biotechnology company’s stock valued at $38,000 after buying an additional 442 shares during the last quarter. Finally, Gould Capital LLC grew its holdings in Corcept Therapeutics by 50.0% in the 3rd quarter. Gould Capital LLC now owns 600 shares of the biotechnology company’s stock valued at $50,000 after buying an additional 200 shares during the last quarter. Institutional investors and hedge funds own 93.61% of the company’s stock.

Key Corcept Therapeutics News

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: HC Wainwright sharply raised multi-year earnings forecasts and increased near-term EPS estimates (including Q2/FY2026 and FY2027–FY2030), maintaining a “Buy” rating and a $75 price target — a major bullish analyst signal that supports higher valuation expectations.
• Positive Sentiment: Market reaction to Corcept’s Q1 update: although the quarter showed a loss, analysts and investors focused on management’s stronger 2026 outlook and new ALS-related data, which helped lift the stock earlier in the day. Article Title
• Positive Sentiment: Zacks Research upgraded CORT from “strong sell” to “hold,” a modestly positive change in sell-side sentiment that can reduce selling pressure. Zacks Research
• Neutral Sentiment: Q1 2026 earnings call transcript is available for investors parsing management commentary and forward guidance for signs of durable revenue growth or margin improvement. Earnings Call Transcript
• Negative Sentiment: Insider selling: William Guyer sold 20,000 shares at an average $51.83 on May 5, materially reducing his position (about a 90% cut), which can be read negatively by some investors. SEC filing: SEC Filing
• Negative Sentiment: Q1 results missed consensus on EPS and revenue came in below estimates — a near-term negative that likely contributed to volatile price action despite the upbeat outlook. (This is the earnings backdrop that makes today’s analyst upgrades and data releases pivotal.)

Corcept Therapeutics Trading Down 2.1%

Shares of NASDAQ:CORT opened at $51.05 on Friday. Corcept Therapeutics Incorporated has a 1-year low of $28.66 and a 1-year high of $91.00. The firm has a market capitalization of $5.48 billion, a PE ratio of 145.86 and a beta of 0.36. The business’s 50 day moving average is $40.09 and its 200-day moving average is $53.80.

Corcept Therapeutics (NASDAQ:CORT) last announced its quarterly earnings data on Thursday, April 30th. The biotechnology company reported ($0.30) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.19). The firm had revenue of $164.90 million for the quarter, compared to analyst estimates of $185.83 million. Corcept Therapeutics had a return on equity of 7.40% and a net margin of 6.14%.Corcept Therapeutics’s revenue for the quarter was up 4.9% compared to the same quarter last year. During the same period in the previous year, the business posted $0.17 EPS. On average, sell-side analysts predict that Corcept Therapeutics Incorporated will post 0.48 EPS for the current year.

Insider Buying and Selling at Corcept Therapeutics

In other news, insider William Guyer sold 20,000 shares of the business’s stock in a transaction on Tuesday, May 5th. The shares were sold at an average price of $51.83, for a total value of $1,036,600.00. Following the sale, the insider owned 2,231 shares in the company, valued at approximately $115,632.73. The trade was a 89.96% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director G Leonard Baker, Jr. bought 100,000 shares of the stock in a transaction dated Tuesday, March 17th. The stock was purchased at an average cost of $33.14 per share, for a total transaction of $3,314,000.00. Following the acquisition, the director owned 1,146,631 shares in the company, valued at $37,999,351.34. The trade was a 9.55% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last three months, insiders sold 86,198 shares of company stock valued at $3,887,769. 20.70% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on the company. HC Wainwright raised their target price on Corcept Therapeutics from $60.00 to $75.00 and gave the company a “buy” rating in a report on Monday. Canaccord Genuity Group lifted their price objective on Corcept Therapeutics from $100.00 to $110.00 and gave the stock a “buy” rating in a report on Thursday, March 26th. Zacks Research raised Corcept Therapeutics from a “strong sell” rating to a “hold” rating in a report on Monday. Truist Financial raised Corcept Therapeutics to a “strong-buy” rating in a report on Wednesday, March 25th. Finally, Piper Sandler lifted their price objective on Corcept Therapeutics from $73.00 to $88.00 and gave the stock an “overweight” rating in a report on Friday, May 1st. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $74.67.

Corcept Therapeutics Profile

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.